Impact of Diabetes on Long‐Term Outcomes of Percutaneous Coronary Intervention for Coronary Bifurcation Lesions
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31476 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Subin Lim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Coronary Artery Disease, Percutaneous Coronary Intervention, Diabetes Mellitus. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Diabetes mellitus (DM) is a well‐known risk factor for cardiovascular diseases, including coronary artery diseases (CAD). Complex percutaneous coronary intervention (PCI) such as PCI for bifurcation lesions often yields poor outcomes, especially in DM patients.
Aims
The effect of DM on cardiovascular outcomes in bifurcation PCI was investigated in this retrospective, multicenter, observational, real‐world registry of 2648 patients with coronary bifurcation lesions undergoing PCI with contemporary drug‐eluting stents (DES).
Methods
The primary outcome was target lesion failure (TLF), defined as a composite of cardiac death, target vessel myocardial infarction and target lesion revascularization. The adjusted outcomes were compared using 1:1 propensity score (PS) matching.
Results
Overall, DM patients were more likely to be older, female, and have hypertension or chronic kidney disease. After PS matching, the cumulative incidence of the primary outcome remained higher in the DM group (7.9% vs. 5.5%, log‐rank p = 0.033). In multivariable analysis, DM (HR, 1.57; 95% CI, 1.02−2.43; p = 0.040), chronic kidney disease (HR, 2.62; 95% CI, 1.27−5.38; p = 0.008), low left ventricular ejection fraction (HR, 1.92; 95% CI, 1.10−3.35; p = 0.022) and the two‐stent technique (HR, 2.18; 95% CI, 1.17−4.05; p = 0.013) were independent predictors of TLF. For patients with intravascular ultrasound‐guided PCI, TLF rates were similar between DM and non‐DM groups (9.1% vs. 7.3%, log‐rank p = 0.347).
Conclusion
For patients with coronary bifurcation lesions undergoing contemporary PCI, 5‐year TLF rates were worse in DM patients. Careful planning and usage of imaging devices may help ameliorate outcomes for DM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
- Division of Cardiology, Department of Internal Medicine, Ewha Womans University Seoul Hospital, Seoul, Korea.
- Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
ORCID-Profile: Subin Lim, Cheol Woong Yu
Zitieren
APA
Lim, S., Hong, S. J., Kim, J. H., Cha, J. J., Joo, H. J., Park, J. H., Yu, C. W., Lim, D. S., Nam, C. W., & COBIS III investigators (2025). Impact of Diabetes on Long‐Term Outcomes of Percutaneous Coronary Intervention for Coronary Bifurcation Lesions. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31476
Vancouver
Lim S, Hong SJ, Kim JH, Cha JJ, Joo HJ, Park JH, et al. Impact of Diabetes on Long‐Term Outcomes of Percutaneous Coronary Intervention for Coronary Bifurcation Lesions. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31476
BibTeX
@article{Lim2025,
author = {Lim, Subin and Hong, Soon Jun and Kim, Ju Hyeon and Cha, Jung-Joon and Joo, Hyung Joon and Park, Jae Hyoung and Yu, Cheol Woong and Lim, Do-Sun and Nam, Chang-Wook and COBIS III investigators, COBIS III investigators},
title = {Impact of Diabetes on Long‐Term Outcomes of Percutaneous Coronary Intervention for Coronary Bifurcation Lesions},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31476}
}
EUVIMED